secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021527
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea Q3 net loss $18.2M; cash $75.2M; pegtarviliase interim data expected Q4 2022
--------------------------------------------------------------------------------

- Cash, equivalents and securities total $75.2M as of Sept 30, 2022; runway into Q4 2023.
- Net loss $18.2M vs $20.3M in Q3 2021; revenue $0.2M from Immedica license.
- Phase 1/2 pegtarviliase trial for Homocystinuria dosing cohort 3 at 1.35 mg/kg; interim data planned Q4 2022.
- MAA for pegzilarginase (Arginase 1 Deficiency) submitted by partner Immedica currently under EMA review.
- Corporate restructuring announced; Jim Kastenmayer appointed interim CEO; permanent CEO search underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/0000950170-22-021527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000095017022021527/agle-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer